Короткий опис (реферат):
As proven earlier, in patients with tuberculosis (TB) the concentration of antituberculosis drugs like isoniazid and rifampicin may differ depending on polymorphism of CYP2C19. The aim of the research was to determine the peculiarities of the pulmonary TB course and its outcome after the in-patient treatment depending on CYP2C19 genotype of the patients. The analysis of medical cards from 83 patients with the primary pulmonary tuberculosis at the end of the in-patient treatment
in Odessa regional TB dispensary was conducted in 2012 with consideration of CYP2C19 genotype. At the beginning of the treatment the processes of disintegration were 3 times less in patients with *1/*1 genotype than in patients with *1/*2 genotype (10.3% versus 31.8%; P<0.05; χ2=5.40), and 6.5 times less than in individuals with *2/*2 genotype (10.3% versus 66.7%; P<0.05; χ2=7.94). At the end of the in-patient treatment the signs of pulmonary destruction were 6.5 times more
common in individuals with *1/*1 genotype than in individuals with *1/*2 genotype (29.3 versus 4.5; Р<0.05; χ2=5.61). The signs of resorption and consolidation in the pulmonary tissue were observed in 74.1% of the patients with *1/*1 genotype, 95.5% of the patients with *1/*2 genotype and 66.7% of the patients with *2/*2 genotype. There were no significant differences between groups in relation to duration of the treatment and development of drug-resistance.
